Press Releases

 
Press Releases
Date Title and Summary View
Apr 19, 2018 SALT LAKE CITY, April 19, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a worldwide leader in personalized medicine, today announced the launch of its new Go Green sustainability initiative. As part of the initiative, Myriad is initially focused on promoting increased recycling and reducing material waste used throughout ...
Apr 17, 2018 SALT LAKE CITY, April 17, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will hold its fiscal third-quarter 2018 sales and earnings conference call with investors and analysts at 7:30 a.m. ET on Tuesday, May 8, 2018.  During the call, Mark C. ...
Apr 2, 2018 SALT LAKE CITY, April 02, 2018 (GLOBE NEWSWIRE) -- Myriad Genetic Laboratories, Inc., a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), announced today that the Japanese Ministry of Health, Labour, and Welfare has granted manufacturing and marketing approval for Myriad's BRACAnalysis®...
Mar 6, 2018 SALT LAKE CITY, March 06, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a worldwide leader in personalized medicine, announced today that the American Association of Clinical Urologists (AACU) have issued a position statement supporting molecular testing for prostate cancer patients, which was also endorsed by ...
Mar 1, 2018 SALT LAKE CITY, March 01, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, continues to demonstrate an unmatched commitment to hereditary cancer risk assessment and genetic testing during National Colorectal Cancer Awareness Month.   As the third ...
Feb 27, 2018 SALT LAKE CITY, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine,  announced today that Mark C. Capone, president and CEO, is scheduled to present at two upcoming investor conferences. On March 13, 2018, Mr. Capone will present at the 38th annual C...
Feb 20, 2018 SALT LAKE CITY, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that the National Comprehensive Cancer Network (NCCN) has updated its medical guidelines for prostate cancer treatment to broadly include biomarker testing in prostate cancer. The changes to the guidelines include new language supporting Pro...
Feb 15, 2018 SALT LAKE CITY, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that a comparative analysis of commercially available prognostic breast cancer tests in patients with early-stage breast cancer has been published in JAMA Oncology.  A key finding is that Myriad's EndoPredict...
Feb 7, 2018 SALT LAKE CITY, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, annou...
Feb 6, 2018 Total Revenues of $194.0 Million GAAP Diluted EPS of $0.45 and Adjusted EPS of $0.31 Up 19 PercentCompany Raises Financial Guidance for Fiscal Year 2018 SALT LAKE CITY, Feb. 06, 2018 (GLOBE NEWSWIRE) -- My...
Page:
1
... NextLast
= add release to Briefcase